Ads
related to: Sage One
Search results
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Zacks via Yahoo Finance· 14 hours agoAdditionally, feedback from...depressive episodes associated with bipolar I or II disorder in adults...
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Zacks via Yahoo Finance· 16 hours agoData from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a...
Sages baseball remains undefeated, Glenwood soccer's offense flourishes against Rochester
FOX Illinois· 21 hours agoMonticello baseball entered Wednesday undefeated and 20-0 on the season, looking to improve on their...
ISU's roster is one step close to being complete with the announcements of its two latest signings
Idaho State Journal· 6 hours agoOne signee — 6-foot-3-inch Aurora Elder from Parris, California, had already publicly committed to...
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Investor's Business Daily· 1 day agoSage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study. Sage stock...
Sage Therapeutics stock target cut on trial results By Investing.com
Investing.com· 1 day agoOn Wednesday, Oppenheimer adjusted its outlook on shares of Sage Therapeutics (NASDAQ:SAGE),...
First Community Mortgage selects Blue Sage platform to scale business - HousingWire
HousingWire· 2 days agoTennessee-based multichannel mortgage lender First Community Mortgage announced on Wednesday that it...
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbush
ETF DAILY NEWS· 1 day agoWedbush reiterated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, Benzinga reports ...
Sage Therapeutics (NASDAQ:SAGE) Downgraded to “Underperform” at Bank of America
ETF DAILY NEWS· 1 day agoBank of America downgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a neutral rating to an underperform rating in a research note released ...
Sage’s cognition drug fails in Parkinson’s study
BioPharma Dive via Yahoo Finance· 2 days agoFollowing negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain...